Free Trial
→ Gold Hits New Highs as Global Markets Spiral (From Premier Gold Co) (Ad) Buy SNY Stock  Free SNY Stock Alerts

Sanofi (SNY) Financials

Sanofi logo
$51.98 -0.53 (-1.01%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$51.79 -0.19 (-0.37%)
As of 05/23/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Sanofi

Annual Income Statements for Sanofi

This table shows Sanofi's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 5,755 5,973 8,955 7,043 15,018 8,019 -32,165 10,110 4,954 4,658
Consolidated Net Income / (Loss)		 5,815 6,013 9,076 7,107 15,062 3,125 5,047 10,255 5,050 4,768
Net Income / (Loss) Continuing Operations		 5,749 5,639 8,647 7,107 15,062 3,239 5,062 4,678 4,719 4,902
Total Pre-Tax Income 		6,933 6,915 10,631 8,826 16,831 7,720 5,042 6,644 5,970 5,697
Total Operating Income		 6,982 6,589 10,535 8,791 7,597 3,424 5,352 7,163 7,013 6,111
Total Gross Profit		 32,172 32,069 30,681 30,468 30,797 28,788 27,745 29,560 25,243 26,014
Total Revenue		 45,840 46,038 43,392 44,338 46,502 42,232 0.00 43,510 36,500 37,878
Operating Revenue		 42,523 41,833 40,279 42,738 44,879 40,543 - 42,130 35,567 37,008
Other Revenue		 3,317 4,205 3,113 1,600 1,622 1,689 - 1,380 933 870
Total Cost of Revenue		 19,315 19,208 15,870 16,330 17,056 13,444 13,087 13,950 11,257 11,864
Operating Cost of Revenue		 19,315 19,208 15,870 16,330 17,056 13,444 13,087 13,950 11,257 11,864
Total Operating Expenses		 19,544 20,241 16,986 19,218 21,848 20,733 18,029 22,397 18,230 19,903
Selling, General & Admin Expense		 9,505 9,882 9,349 10,814 11,472 11,092 11,284 12,099 9,971 10,194
Research & Development Expense		 7,654 7,198 6,955 6,442 6,755 6,756 6,746 6,573 5,441 5,522
Amortization Expense		 1,810 2,114 1,930 1,788 2,054 2,408 - 2,242 1,780 2,322
Other Operating Expenses / (Income)		 -1,127 -1,083 -1,941 -972 - 476 - -4.80 134 168
Impairment Charge		 257 991 -459 217 403 - - 352 202 833
Restructuring Charge		 1,445 1,139 1,152 928 1,330 - - 878 925 864
Total Other Income / (Expense), net		 -49 326 95 35 9,234 -336 -498 -519 -1,043 -414
Interest & Investment Income		 537 646 219 45 65 158 - 177 72 193
Other Income / (Expense), net		 -586 -320 -124 -10 9,169 -494 - -696 -1,114 -607
Income Tax Expense		 1,246 1,125 2,042 1,763 2,207 136 551 2,069 1,394 770
Other Gains / (Losses), net		 62 -150 59 44 439 286 - 102 143 -24
Other Adjustments to Consolidated Net Income / (Loss)		 66 374 429 - - - - 5,577 330 -135
Net Income / (Loss) Attributable to Noncontrolling Interest		 -60 -40 -121 -63 -44 -35 - -145 -96 110
Basic Earnings per Share		 $4.60 $4.77 $7.16 - $9.81 - - $8.05 $3.66 $3.56
Weighted Average Basic Shares Outstanding		 1.26B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.26B 1.29B 1.42B
Diluted Earnings per Share		 $4.59 $4.76 $7.12 - $9.76 - - $7.98 $3.63 $3.53
Weighted Average Diluted Shares Outstanding		 1.26B 1.26B 1.26B 1.26B 1.26B 1.26B 1.25B 1.27B 1.30B 1.43B
Weighted Average Basic & Diluted Shares Outstanding		 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B - -

Quarterly Income Statements for Sanofi

No quarterly income statements for Sanofi are available.

Annual Cash Flow Statements for Sanofi

This table details how cash moves in and out of Sanofi's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 -3,522 -6,308 2,822 -4,320 -5,880 2,808 3,880 -5,760 8,417 1,963
Net Cash From Operating Activities		 -3,923 -753 11,261 11,909 -10,153 8,658 6,349 -6,439 3,396 9,007
Net Cash From Continuing Operating Activities		 -3,923 -753 10,311 8,053 -10,153 7,023 7,804 -6,439 3,396 -819
Net Income / (Loss) Continuing Operations		 66 0.00 8,955 7,043 0.00 2,977 4,913 -5,577 -330 4,523
Consolidated Net Income / (Loss)		 66 - 8,955 7,043 - 3,091 4,928 - - 4,658
Depreciation Expense		 3,712 - - - - - - - 3,473 -4,646
Non-Cash Adjustments To Reconcile Net Income		 -7,517 494 -426 -543 -9,720 2,724 1,740 115 254 -1,843
Changes in Operating Assets and Liabilities, net		 -184 -1,248 -1,236 1,553 -432 1,322 1,151 -977 - 1,146
Net Cash From Investing Activities		 1,512 -5,274 -2,220 -8,260 4,559 1,328 14,725 643 0.00 -3,272
Net Cash From Continuing Investing Activities		 1,512 -5,274 -2,265 -8,183 4,559 826 -12,239 643 0.00 -3,272
Sale of Property, Plant & Equipment		 1,512 893 1,434 765 1,121 1,374 2,476 643 - 229
Net Cash From Financing Activities		 -925 -280 -6,227 -7,986 -286 4,706 4,503 36 5,021 -3,888
Net Cash From Continuing Financing Activities		 -925 -280 -6,212 -7,517 -286 -4,533 4,975 36 5,021 -3,888
Repayment of Debt		 -925 -280 -3,207 -2,705 -286 -2,619 -901 0.00 - -985
Effect of Exchange Rate Changes		 -186 - - 17 - 10 1.14 - - -252

Quarterly Cash Flow Statements for Sanofi

No quarterly cash flow statements for Sanofi are available.

Annual Balance Sheets for Sanofi

This table presents Sanofi's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 137,459 139,894 135,567 136,090 139,767 126,400 127,508 119,900 110,122 111,176
Total Current Assets		 30,120 33,911 36,401 34,592 41,172 32,109 28,131 31,658 28,079 27,085
Cash & Equivalents		 7,702 9,635 13,625 11,429 16,999 10,580 7,926 12,391 10,807 9,940
Accounts Receivable		 7,946 9,329 9,012 8,565 9,151 8,907 8,309 8,668 7,691 8,025
Inventories, net		 9,762 10,693 9,585 9,864 10,203 8,971 8,558 8,190 7,255 7,080
Current Deferred & Refundable Income Taxes		 749 433 400 693 1,476 907 1,023 - - -
Other Current Assets		 3,960 3,822 3,779 4,042 3,344 2,744 2,315 2,408 2,326 2,041
Plant, Property, & Equipment, net		 10,445 11,239 10,558 11,350 11,440 10,905 11,046 11,507 10,540 10,804
Plant, Property & Equipment, gross		 10,445 11,239 10,558 11,350 11,440 10,905 11,046 11,507 10,540 10,804
Total Noncurrent Assets		 96,894 94,745 88,608 90,148 87,155 82,837 88,075 76,736 71,503 73,287
Long-Term Investments		 327 469 724 283 246 4,030 3,894 3,420 3,042 2,908
Goodwill		 44,907 54,651 53,374 54,390 54,195 49,962 50,627 48,367 42,382 42,980
Intangible Assets		 23,423 26,902 23,150 24,228 22,405 18,527 25,052 15,712 11,445 13,067
Noncurrent Deferred & Refundable Income Taxes		 8,826 7,318 6,015 5,402 5,404 6,050 5,280 5,155 4,913 5,122
Other Noncurrent Operating Assets		 19,410 5,406 5,344 5,845 4,905 4,268 3,222 4,082 9,722 9,211
Total Liabilities & Shareholders' Equity		 137,459 139,894 135,567 136,090 139,767 126,400 127,508 119,900 110,122 111,176
Total Liabilities		 48,489 49,250 48,397 50,354 53,562 37,644 38,326 48,708 48,142 64,850
Total Current Liabilities		 30,186 26,778 25,647 24,102 23,513 11,370 9,232 18,575 17,298 18,140
Short-Term Debt		 4,357 2,262 4,465 3,603 3,380 5,111 3,013 1,532 1,856 3,733
Accounts Payable		 7,816 8,106 7,289 6,995 6,468 5,963 5,769 5,565 4,520 4,147
Current Deferred & Payable Income Tax Liabilities		 721 660 614 350 738 290 449 - - -
Other Current Liabilities		 15,086 15,735 13,269 13,155 12,927 - - 11,478 10,922 10,259
Total Noncurrent Liabilities		 26,684 30,867 29,522 33,859 38,946 37,049 40,054 31,366 30,844 46,711
Long-Term Debt		 12,205 15,871 15,894 19,380 24,121 22,592 25,187 17,209 17,689 14,253
Capital Lease Obligations		 1,703 1,941 2,037 2,081 1,137 1,108 0.00 0.00 - -
Noncurrent Deferred & Payable Income Tax Liabilities		 3,807 4,092 4,087 4,138 4,279 2,574 3,907 1,928 2,411 3,146
Other Noncurrent Operating Liabilities		 589 554 721 653 473 - - 10,996 9,293 9,963
Other Noncurrent Nonoperating Liabilities		 2,206 14 11 0.00 39 - - 0.00 1,257 1,068
Total Equity & Noncontrolling Interests		 80,952 82,596 80,791 78,525 77,447 66,471 67,566 71,395 62,352 127,855
Total Preferred & Common Equity		 80,590 82,249 80,398 78,129 77,269 66,276 67,384 69,959 60,724 126,321
Total Common Equity		 80,227 81,903 80,004 77,733 77,091 0.00 0.00 69,756 60,545 126,321
Common Stock		 80,227 81,903 80,004 77,733 77,091 - - 69,756 60,545 63,073
Noncontrolling Interest		 362 346 394 396 178 195 182 1,435 1,628 1,534

Quarterly Balance Sheets for Sanofi

This table presents Sanofi's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q4 2023 Q4 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 137,459 139,894 135,567
Total Current Assets		 30,120 33,911 36,401
Cash & Equivalents		 7,702 9,635 13,625
Accounts Receivable		 7,946 9,329 9,012
Inventories, net		 9,762 10,693 9,585
Current Deferred & Refundable Income Taxes		 749 433 400
Other Current Assets		 3,960 3,822 3,779
Plant, Property, & Equipment, net		 10,445 11,239 10,558
Plant, Property & Equipment, gross		 10,445 11,239 10,558
Total Noncurrent Assets		 96,894 94,745 88,608
Long-Term Investments		 327 469 724
Goodwill		 44,907 54,651 53,374
Intangible Assets		 23,423 26,902 23,150
Noncurrent Deferred & Refundable Income Taxes		 8,826 7,318 6,015
Other Noncurrent Operating Assets		 19,410 5,406 5,344
Total Liabilities & Shareholders' Equity		 137,459 139,894 135,567
Total Liabilities		 48,489 49,250 48,397
Total Current Liabilities		 30,186 26,778 25,647
Short-Term Debt		 4,357 2,262 4,465
Accounts Payable		 7,816 8,106 7,289
Current Deferred & Payable Income Tax Liabilities		 721 660 614
Other Current Liabilities		 15,086 15,735 13,269
Total Noncurrent Liabilities		 26,684 30,867 29,522
Long-Term Debt		 12,205 15,871 15,894
Capital Lease Obligations		 1,703 1,941 2,037
Noncurrent Deferred & Payable Income Tax Liabilities		 3,807 4,092 4,087
Other Noncurrent Operating Liabilities		 589 554 721
Other Noncurrent Nonoperating Liabilities		 2,206 14 11
Total Equity & Noncontrolling Interests		 80,952 82,596 80,791
Total Preferred & Common Equity		 80,590 82,249 80,398
Total Common Equity		 80,227 81,903 80,004
Common Stock		 80,227 81,903 80,004
Noncontrolling Interest		 362 346 394

Annual Metrics And Ratios for Sanofi

This table displays calculated financial ratios and metrics derived from Sanofi's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -0.43% 6.10% -2.13% -4.65% 10.11% 0.00% -100.00% 19.21% -3.64% 0.00%
EBITDA Growth		 20.58% -32.07% 16.77% -43.84% 252.53% -0.25% -38.55% -7.07% 993.13% 0.00%
EBIT Growth		 2.03% -39.79% 18.57% -47.63% 472.19% -45.25% -17.25% 9.65% 7.18% 0.00%
NOPAT Growth		 3.81% -35.19% 21.00% 6.57% 96.23% -29.44% -3.36% -8.23% 1.72% 0.00%
Net Income Growth		 -3.29% -33.75% 27.72% -52.82% 381.92% -38.08% -50.78% 103.09% 5.91% 0.00%
EPS Growth		 -3.60% -33.24% 0.00% 0.00% 0.00% 0.00% 0.00% 119.73% 2.80% 0.00%
Operating Cash Flow Growth		 -420.76% -106.69% -5.44% 217.30% -217.26% 36.38% 198.60% -289.60% -62.30% 0.00%
Free Cash Flow Firm Growth		 4,312.95% -99.09% 121.34% -50.92% 81.90% 123.68% -41,940.79% 99.44% 0.00% 0.00%
Invested Capital Growth		 0.76% 5.67% -3.88% 1.49% -4.66% -2.75% 42.07% 7.23% 31.58% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 70.18% 69.66% 70.71% 68.72% 66.23% 68.17% 0.00% 67.94% 69.16% 68.68%
EBITDA Margin		 22.05% 18.21% 28.44% 23.84% 40.47% 12.64% 0.00% 20.02% 25.67% 2.26%
Operating Margin		 15.23% 14.31% 24.28% 19.83% 16.34% 8.11% 0.00% 16.46% 19.21% 16.13%
EBIT Margin		 13.95% 13.62% 23.99% 19.80% 36.06% 6.94% 0.00% 14.86% 16.16% 14.53%
Profit (Net Income) Margin		 12.69% 13.06% 20.92% 16.03% 32.39% 7.40% 0.00% 23.57% 13.83% 12.59%
Tax Burden Percent		 83.88% 86.96% 85.38% 80.52% 89.49% 40.49% 100.11% 154.35% 84.58% 83.69%
Interest Burden Percent		 108.40% 110.31% 102.11% 100.52% 100.39% 263.46% 94.20% 102.73% 101.21% 103.51%
Effective Tax Rate		 17.98% 16.27% 19.21% 19.98% 13.12% 1.76% 10.92% 31.13% 23.35% 13.52%
Return on Invested Capital (ROIC)		 5.67% 5.63% 8.76% 7.15% 6.60% 3.24% 0.00% 6.89% 8.84% 10.06%
ROIC Less NNEP Spread (ROIC-NNEP)		 6.13% 8.69% 11.99% 7.51% 36.75% 2.59% 0.00% 118.92% 9.79% 10.75%
Return on Net Nonoperating Assets (RNNOA)		 1.44% 1.73% 2.63% 1.96% 14.33% 1.42% 0.00% 8.45% -3.53% -6.33%
Return on Equity (ROE)		 7.11% 7.36% 11.39% 9.11% 20.93% 4.66% 7.26% 15.34% 5.31% 3.73%
Cash Return on Invested Capital (CROIC)		 4.91% 0.11% 12.72% 5.68% 11.38% 6.02% -29.45% -0.09% -18.44% 0.00%
Operating Return on Assets (OROA)		 4.61% 4.55% 7.67% 6.37% 12.60% 2.31% 0.00% 5.62% 5.33% 4.95%
Return on Assets (ROA)		 4.19% 4.37% 6.68% 5.15% 11.32% 2.46% 0.00% 8.92% 4.56% 4.29%
Return on Common Equity (ROCE)		 7.05% 7.29% 11.28% 9.05% 11.21% 0.00% 3.65% 14.94% 5.22% 3.68%
Return on Equity Simple (ROE_SIMPLE)		 7.22% 7.31% 11.29% 9.10% 19.49% 4.72% 7.49% 14.66% 8.32% 3.77%
Net Operating Profit after Tax (NOPAT)		 5,727 5,517 8,511 7,034 6,601 3,364 4,767 4,933 5,375 5,284
NOPAT Margin		 12.49% 11.98% 19.62% 15.87% 14.19% 7.97% 0.00% 11.34% 14.73% 13.95%
Net Nonoperating Expense Percent (NNEP)		 -0.46% -3.06% -3.23% -0.35% -30.15% 0.65% -1.38% -112.04% -0.95% -0.69%
Return On Investment Capital (ROIC_SIMPLE)		 5.77% 5.37% 8.25% 6.79% 6.22% 3.53% 4.98% 5.47% 6.56% 3.62%
Cost of Revenue to Revenue		 42.14% 41.72% 36.57% 36.83% 36.68% 31.83% 0.00% 32.06% 30.84% 31.32%
SG&A Expenses to Revenue		 20.74% 21.46% 21.55% 24.39% 24.67% 26.27% 0.00% 27.81% 27.32% 26.91%
R&D to Revenue		 16.70% 15.64% 16.03% 14.53% 14.53% 16.00% 0.00% 15.11% 14.91% 14.58%
Operating Expenses to Revenue		 42.63% 43.97% 39.15% 43.34% 46.98% 49.09% 0.00% 51.48% 49.95% 52.55%
Earnings before Interest and Taxes (EBIT)		 6,396 6,269 10,411 8,781 16,767 2,930 5,352 6,468 5,899 5,503
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 10,108 8,383 12,341 10,569 18,820 5,339 5,352 8,709 9,371 857
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.76 0.73 0.71 0.72 0.68 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 5.13 171.54 16.26 0.00 106.80 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1.33 1.31 1.30 1.26 1.13 1.23 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 10.60 10.07 6.32 7.93 3.48 6.46 0.00 0.00 0.00 0.00
Dividend Yield		 8.16% 3.98% 0.00% 4.32% 4.07% 4.14% 5.18% 5.03% 5.60% 5.36%
Earnings Yield		 9.43% 9.93% 15.83% 12.61% 28.71% 15.47% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.71 0.70 0.68 0.70 0.65 0.65 0.57 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1.56 1.53 1.50 1.57 1.37 1.57 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 7.08 8.41 5.27 6.59 3.39 12.40 11.19 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 11.19 11.24 6.25 7.93 3.81 22.60 11.19 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 12.50 12.77 7.64 9.90 9.68 19.69 12.56 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 5.77 5.85 0.00 7.65 9.43 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 14.44 627.07 5.26 12.47 5.62 10.59 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.23 0.24 0.28 0.32 0.37 0.43 0.42 0.26 0.31 0.14
Long-Term Debt to Equity		 0.17 0.22 0.22 0.27 0.33 0.36 0.37 0.24 0.28 0.11
Financial Leverage		 0.24 0.20 0.22 0.26 0.39 0.55 0.29 0.07 -0.36 -0.59
Leverage Ratio		 1.70 1.69 1.71 1.77 1.85 1.89 1.78 1.72 1.16 0.87
Compound Leverage Factor		 1.84 1.86 1.74 1.78 1.86 4.99 1.68 1.77 1.18 0.90
Debt to Total Capital		 18.41% 19.55% 21.70% 24.20% 27.00% 30.24% 29.45% 20.79% 23.87% 12.33%
Short-Term Debt to Total Capital		 4.39% 2.20% 4.33% 3.48% 3.19% 5.36% 3.15% 1.70% 2.27% 2.56%
Long-Term Debt to Total Capital		 14.02% 17.35% 17.38% 20.72% 23.81% 24.87% 26.30% 19.09% 21.60% 9.77%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.37% 0.34% 0.38% 0.38% 0.17% 0.20% 0.19% 1.59% 1.99% 1.05%
Common Equity to Total Capital		 80.86% 79.77% 77.53% 75.04% 72.67% 0.00% 0.00% 77.39% 73.93% 86.62%
Debt to EBITDA		 1.81 2.39 1.81 2.37 1.52 5.40 5.27 2.15 2.09 20.98
Net Debt to EBITDA		 1.01 1.19 0.65 1.26 0.61 2.66 3.06 0.34 0.61 5.99
Long-Term Debt to EBITDA		 1.38 2.12 1.45 2.03 1.34 4.44 4.71 1.98 1.89 16.63
Debt to NOPAT		 3.19 3.64 2.63 3.56 4.34 8.56 5.92 3.80 3.64 3.40
Net Debt to NOPAT		 1.79 1.81 0.95 1.90 1.73 4.22 3.44 0.59 1.06 0.97
Long-Term Debt to NOPAT		 2.43 3.23 2.11 3.05 3.83 7.05 5.28 3.49 3.29 2.70
Altman Z-Score		 1.24 1.27 1.37 1.30 1.47 1.43 0.99 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.87% 0.91% 0.99% 0.74% 46.43% 100.00% 49.80% 2.58% 1.76% 1.20%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 1.00 1.27 1.42 1.44 1.75 2.82 3.05 1.70 1.62 1.49
Quick Ratio		 0.52 0.71 0.88 0.83 1.11 1.71 1.76 1.13 1.07 0.99
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 4,959 112 12,360 5,584 11,378 6,255 -26,417 -63 -11,217 0.00
Operating Cash Flow to CapEx		 0.00% -32.44% 1,379.55% 769.71% -713.39% 0.00% 0.00% 0.00% 0.00% 323.70%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -53.06 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 12.75 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 17.72 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.33 0.33 0.32 0.32 0.35 0.33 0.00 0.38 0.33 0.34
Accounts Receivable Turnover		 5.31 5.02 4.94 5.01 5.15 4.91 0.00 5.32 4.64 4.72
Inventory Turnover		 1.89 1.89 1.63 1.63 1.78 1.53 1.56 1.81 1.57 1.68
Fixed Asset Turnover		 4.23 4.22 3.96 3.89 4.16 3.85 0.00 3.95 3.42 3.51
Accounts Payable Turnover		 2.43 2.50 2.22 2.43 2.74 2.29 2.31 2.77 2.60 2.86
Days Sales Outstanding (DSO)		 68.78 72.70 73.93 72.92 70.87 74.40 0.00 68.62 78.58 77.33
Days Inventory Outstanding (DIO)		 193.27 192.67 223.65 224.26 205.16 237.96 233.54 202.05 232.38 217.82
Days Payable Outstanding (DPO)		 150.44 146.27 164.25 150.46 133.01 159.27 158.06 131.95 140.52 127.59
Cash Conversion Cycle (CCC)		 111.60 119.10 133.33 146.72 143.02 153.09 0.00 138.72 170.45 167.55
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 101,411 100,643 95,239 99,088 97,638 102,415 105,306 74,122 69,126 52,533
Invested Capital Turnover		 0.45 0.47 0.45 0.45 0.46 0.41 0.00 0.61 0.60 0.72
Increase / (Decrease) in Invested Capital		 768 5,404 -3,849 1,450 -4,777 -2,891 31,185 4,996 16,593 0.00
Enterprise Value (EV)		 71,599 70,468 65,022 69,612 63,888 66,223 59,898 0.00 0.00 0.00
Market Capitalization		 61,001 60,152 56,581 55,865 52,316 51,827 43,335 0.00 0.00 0.00
Book Value per Share		 $63.43 $64.96 $63.91 $62.06 $61.48 $0.00 $0.00 $55.50 $47.06 $89.01
Tangible Book Value per Share		 $9.41 $0.28 $2.78 ($0.71) $0.39 ($54.99) ($60.35) $4.52 $5.22 $49.51
Total Capital		 99,216 102,670 103,188 103,589 106,085 95,282 95,767 90,135 81,897 145,842
Total Debt		 18,264 20,074 22,396 25,064 28,638 28,811 28,201 18,741 19,545 17,987
Total Long-Term Debt		 13,908 17,812 17,931 21,461 25,258 23,700 25,187 17,209 17,689 14,253
Net Debt		 10,235 9,970 8,047 13,352 11,394 14,201 16,381 2,930 5,696 5,139
Capital Expenditures (CapEx)		 -1,512 2,322 816 1,547 1,423 -1,374 -2,476 -643 0.00 2,783
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3,411 -240 1,594 2,664 4,040 15,271 13,987 2,224 1,829 2,739
Debt-free Net Working Capital (DFNWC)		 4,292 9,395 15,219 14,093 21,038 25,850 21,913 14,614 12,637 12,679
Net Working Capital (NWC)		 -65 7,133 10,754 10,491 17,658 20,739 18,899 13,083 10,781 8,946
Net Nonoperating Expense (NNE)		 -88 -497 -565 -72 -8,462 238 -280 -5,322 326 517
Net Nonoperating Obligations (NNO)		 20,459 18,048 14,448 20,563 20,191 35,944 37,740 2,727 6,774 -75,321
Total Depreciation and Amortization (D&A)		 3,712 2,114 1,930 1,788 2,054 2,408 0.00 2,242 3,473 -4,646
Debt-free, Cash-free Net Working Capital to Revenue		 -7.44% -0.52% 3.67% 6.01% 8.69% 36.16% 0.00% 5.11% 5.01% 7.23%
Debt-free Net Working Capital to Revenue		 9.36% 20.41% 35.07% 31.79% 45.24% 61.21% 0.00% 33.59% 34.62% 33.47%
Net Working Capital to Revenue		 -0.14% 15.49% 24.78% 23.66% 37.97% 49.11% 0.00% 30.07% 29.54% 23.62%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $4.60 $0.00 $6.69 $0.00 $0.00 $2.51 $3.45 $8.06 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 1.26B 1.26B 1.26B 0.00 1.25B 1.25B 1.25B 1.51B 0.00 0.00
Adjusted Diluted Earnings per Share		 $4.59 $0.00 $6.66 $0.00 $0.00 $2.50 $3.43 $8.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 1.26B 1.26B 1.26B 0.00 1.25B 1.26B 1.26B 1.52B 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.25B 1.25B 1.25B 0.00 1.25B 1.25B 1.25B 1.25B 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 7,123 7,301 9,071 7,951 7,963 3,364 4,767 5,958 6,069 6,752
Normalized NOPAT Margin		 15.54% 15.86% 20.91% 17.93% 17.12% 7.97% 0.00% 13.69% 16.63% 17.83%
Pre Tax Income Margin		 15.12% 15.02% 24.50% 19.91% 36.20% 18.28% 0.00% 15.27% 16.36% 15.04%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 10.75 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 9.58 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 15.72 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 14.55 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 50.27% 64.60% 0.00% 138.17% 85.87% 0.00% 0.00% 84.46%
Augmented Payout Ratio		 0.00% 0.00% 56.13% 70.68% 0.00% 138.74% 110.84% 0.00% 0.00% 125.11%

Quarterly Metrics And Ratios for Sanofi

No quarterly metrics and ratios for Sanofi are available.

Frequently Asked Questions About Sanofi's Financials

When does Sanofi's financial year end?

According to the most recent income statement we have on file, Sanofi's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Sanofi's net income changed over the last 9 years?

Sanofi's net income appears to be on an upward trend, with a most recent value of $5.82 billion in 2024, rising from $4.77 billion in 2015. The previous period was $6.01 billion in 2023. Check out Sanofi's forecast to explore projected trends and price targets.

What is Sanofi's operating income?
Sanofi's total operating income in 2024 was $6.98 billion, based on the following breakdown:
  • Total Gross Profit: $32.17 billion
  • Total Operating Expenses: $19.54 billion
How has Sanofi revenue changed over the last 9 years?

Over the last 9 years, Sanofi's total revenue changed from $37.88 billion in 2015 to $45.84 billion in 2024, a change of 21.0%.

How much debt does Sanofi have?

Sanofi's total liabilities were at $48.49 billion at the end of 2024, a 1.5% decrease from 2023, and a 25.2% decrease since 2015.

How much cash does Sanofi have?

In the past 9 years, Sanofi's cash and equivalents has ranged from $7.70 billion in 2024 to $17.00 billion in 2020, and is currently $7.70 billion as of their latest financial filing in 2024.

How has Sanofi's book value per share changed over the last 9 years?

Over the last 9 years, Sanofi's book value per share changed from 89.01 in 2015 to 63.43 in 2024, a change of -28.7%.


Related Companies

This page (NASDAQ:SNY) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...
Crypto 101 Media | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored